Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease
Summary Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infec...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-01, Vol.31 (1), p.20-34 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 20 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 31 |
| creator | SHALE, M. J. SEOW, C. H. COFFIN, C. S. KAPLAN, G. G. PANACCIONE, R. GHOSH, S. |
| description | Summary
Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice.
Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease.
Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables.
Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF.
Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment. |
| doi_str_mv | 10.1111/j.1365-2036.2009.04112.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733387453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733387453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4482-f90c390dcbdd567d0e41c348fc954b45c0ff21594a10e64fafdea1c932873eb43</originalsourceid><addsrcrecordid>eNqNkMuKFDEUhoMoTjv6CpKNuKry5FI3wcUweIMBRcZ1SKVOmDSpqjap6p7e-Qg-o09iYjfj1gSSA_n-5OQjhDIoWRpvtiUTdVVwEHXJAboSJGO8vH9ENg8Hj8kGeN0VvGXigjyLcQsAdQP8KblgXd2yNDdk_w33Dg9Uh8UZj2-puQvz5Azdu6A9dZNFs7h5ShVd7pDqaXG_f_5a1nFeA53QhDm6SK02yxwyEfTuSNOaAynt9TjqdHSk_XxATwcXUUd8Tp5Y7SO-OO-X5PuH97fXn4qbLx8_X1_dFEbKlhe2AyM6GEw_DFXdDICSGSFba7pK9rIyYC1nVSc1A6yl1XZAzUwneNsI7KW4JK9P9-7C_GPFuKjRRYPe6wnnNapGCNE2shKJbE9k_lEMaNUuuFGHo2KgsnS1Vdmtym5Vlq7-Slf3Kfry_Mjajzj8C54tJ-DVGdDRaG-DnoyLDxznHCRvcg_vTtzBeTz-dwPq6uttrsQfbS2gSA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733387453</pqid></control><display><type>article</type><title>Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><creator>SHALE, M. J. ; SEOW, C. H. ; COFFIN, C. S. ; KAPLAN, G. G. ; PANACCIONE, R. ; GHOSH, S.</creator><creatorcontrib>SHALE, M. J. ; SEOW, C. H. ; COFFIN, C. S. ; KAPLAN, G. G. ; PANACCIONE, R. ; GHOSH, S.</creatorcontrib><description>Summary
Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice.
Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease.
Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables.
Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF.
Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2009.04112.x</identifier><identifier>PMID: 19681818</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; Chronic Disease ; Digestive system ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - antagonists & inhibitors ; Infectious diseases ; Inflammatory Bowel Diseases - complications ; Inflammatory Bowel Diseases - drug therapy ; Medical sciences ; Opportunistic Infections - chemically induced ; Opportunistic Infections - drug therapy ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Practice Guidelines as Topic ; Recurrence ; Risk Factors ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumor Necrosis Factor-alpha - adverse effects ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Viral diseases ; Virus Activation ; Virus Diseases - chemically induced ; Virus Diseases - etiology</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-01, Vol.31 (1), p.20-34</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4482-f90c390dcbdd567d0e41c348fc954b45c0ff21594a10e64fafdea1c932873eb43</citedby><cites>FETCH-LOGICAL-c4482-f90c390dcbdd567d0e41c348fc954b45c0ff21594a10e64fafdea1c932873eb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2009.04112.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2009.04112.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22204273$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19681818$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHALE, M. J.</creatorcontrib><creatorcontrib>SEOW, C. H.</creatorcontrib><creatorcontrib>COFFIN, C. S.</creatorcontrib><creatorcontrib>KAPLAN, G. G.</creatorcontrib><creatorcontrib>PANACCIONE, R.</creatorcontrib><creatorcontrib>GHOSH, S.</creatorcontrib><title>Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice.
Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease.
Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables.
Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF.
Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.</description><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Digestive system</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - antagonists & inhibitors</subject><subject>Infectious diseases</subject><subject>Inflammatory Bowel Diseases - complications</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Medical sciences</subject><subject>Opportunistic Infections - chemically induced</subject><subject>Opportunistic Infections - drug therapy</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Practice Guidelines as Topic</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumor Necrosis Factor-alpha - adverse effects</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Viral diseases</subject><subject>Virus Activation</subject><subject>Virus Diseases - chemically induced</subject><subject>Virus Diseases - etiology</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMuKFDEUhoMoTjv6CpKNuKry5FI3wcUweIMBRcZ1SKVOmDSpqjap6p7e-Qg-o09iYjfj1gSSA_n-5OQjhDIoWRpvtiUTdVVwEHXJAboSJGO8vH9ENg8Hj8kGeN0VvGXigjyLcQsAdQP8KblgXd2yNDdk_w33Dg9Uh8UZj2-puQvz5Azdu6A9dZNFs7h5ShVd7pDqaXG_f_5a1nFeA53QhDm6SK02yxwyEfTuSNOaAynt9TjqdHSk_XxATwcXUUd8Tp5Y7SO-OO-X5PuH97fXn4qbLx8_X1_dFEbKlhe2AyM6GEw_DFXdDICSGSFba7pK9rIyYC1nVSc1A6yl1XZAzUwneNsI7KW4JK9P9-7C_GPFuKjRRYPe6wnnNapGCNE2shKJbE9k_lEMaNUuuFGHo2KgsnS1Vdmtym5Vlq7-Slf3Kfry_Mjajzj8C54tJ-DVGdDRaG-DnoyLDxznHCRvcg_vTtzBeTz-dwPq6uttrsQfbS2gSA</recordid><startdate>201001</startdate><enddate>201001</enddate><creator>SHALE, M. J.</creator><creator>SEOW, C. H.</creator><creator>COFFIN, C. S.</creator><creator>KAPLAN, G. G.</creator><creator>PANACCIONE, R.</creator><creator>GHOSH, S.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201001</creationdate><title>Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease</title><author>SHALE, M. J. ; SEOW, C. H. ; COFFIN, C. S. ; KAPLAN, G. G. ; PANACCIONE, R. ; GHOSH, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4482-f90c390dcbdd567d0e41c348fc954b45c0ff21594a10e64fafdea1c932873eb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Digestive system</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - antagonists & inhibitors</topic><topic>Infectious diseases</topic><topic>Inflammatory Bowel Diseases - complications</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Medical sciences</topic><topic>Opportunistic Infections - chemically induced</topic><topic>Opportunistic Infections - drug therapy</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Practice Guidelines as Topic</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumor Necrosis Factor-alpha - adverse effects</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Viral diseases</topic><topic>Virus Activation</topic><topic>Virus Diseases - chemically induced</topic><topic>Virus Diseases - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHALE, M. J.</creatorcontrib><creatorcontrib>SEOW, C. H.</creatorcontrib><creatorcontrib>COFFIN, C. S.</creatorcontrib><creatorcontrib>KAPLAN, G. G.</creatorcontrib><creatorcontrib>PANACCIONE, R.</creatorcontrib><creatorcontrib>GHOSH, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHALE, M. J.</au><au>SEOW, C. H.</au><au>COFFIN, C. S.</au><au>KAPLAN, G. G.</au><au>PANACCIONE, R.</au><au>GHOSH, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-01</date><risdate>2010</risdate><volume>31</volume><issue>1</issue><spage>20</spage><epage>34</epage><pages>20-34</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background Anti‐Tumour necrosis factor (TNF) therapy is now well established in the treatment of inflammatory bowel disease and the risk of opportunistic infection is recognized. However, specific considerations regarding screening, detection, prevention and treatment of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease are not widely adopted in practice.
Aim To provide a detailed and comprehensive review of the relevance of chronic viral infections in the context of anti‐TNF therapy in inflammatory bowel disease.
Methods Literature search was conducted using Medline, Pubmed and Embase using the terms viral infection, hepatitis, herpes, CMV, EBV, HPV, anti‐TNF, infliximab, adalimumab, certolizumab pegol and etanercept. Hepatitis B and C and HIV had the largest literature associated and these have been summarized in Tables.
Results Particular risks are associated with the use of anti‐TNF drugs in patients with hepatitis B infection, in whom reactivation is common unless anti‐viral prophylaxis is used. Reactivation of herpes zoster is the most common viral problem associated with anti‐TNF treatment, and may be particularly severe. Primary varicella infection may present with atypical features in patients on anti‐TNF.
Conclusion Appreciation of risks of chronic viral disease associated with anti‐TNF therapy may permit early recognition, prophylaxis and treatment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19681818</pmid><doi>10.1111/j.1365-2036.2009.04112.x</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-01, Vol.31 (1), p.20-34 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733387453 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection) |
| subjects | Biological and medical sciences Chronic Disease Digestive system Gastroenterology. Liver. Pancreas. Abdomen Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - antagonists & inhibitors Infectious diseases Inflammatory Bowel Diseases - complications Inflammatory Bowel Diseases - drug therapy Medical sciences Opportunistic Infections - chemically induced Opportunistic Infections - drug therapy Other diseases. Semiology Pharmacology. Drug treatments Practice Guidelines as Topic Recurrence Risk Factors Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumor Necrosis Factor-alpha - adverse effects Tumor Necrosis Factor-alpha - antagonists & inhibitors Viral diseases Virus Activation Virus Diseases - chemically induced Virus Diseases - etiology |
| title | Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T19%3A29%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20article:%20chronic%20viral%20infection%20in%20the%20anti%E2%80%90tumour%20necrosis%20factor%20therapy%20era%20in%20inflammatory%20bowel%20disease&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=SHALE,%20M.%20J.&rft.date=2010-01&rft.volume=31&rft.issue=1&rft.spage=20&rft.epage=34&rft.pages=20-34&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2009.04112.x&rft_dat=%3Cproquest_cross%3E733387453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733387453&rft_id=info:pmid/19681818&rfr_iscdi=true |